regulusrx.com (RGLS): Price/Earnings to Growth Ratio
Will Regulus Therapeutics (RGLS) become a leader in the kidney therapy niche through its unique RNA developments? This PEG ratio chart confirms the potential for expansion in the polycystic kidney disease segment, where the value is fixed at 0.00. The issuer's financial stability relies on future insurance payments and licensing fees from partners involved in creating innovative genetic medicines.
Regulus Therapeutics (RGLS) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Regulus Therapeutics|RGLS - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio regulusrx.com|RGLS - Company Aggregate Debts|Debt to Net Assets Ratio Regulus Therapeutics Inc|RGLS - Company Long-Term Debts|Short-Term Debt Regulus Therapeutics|Intermediate Coverage Ratio regulusrx.com
- company profitability and valuation multiples indicators:
RGLS - Net Profit|Projected Future Earnings Regulus Therapeutics|RGLS - Price to Earnings Ratio|Price to Expected Earnings Ratio Regulus|RGLS - PEG Multiple|Company Value to EBITDA Regulus Therapeutics Inc|RGLS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Regulus Therapeutics|RGLS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months regulusrx.com|RGLS - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Regulus Therapeutics
General company analysis:Regulus Therapeutics, Inc., RGLS
The PEG ratio compares the P/E multiple with earnings growth rates to determine whether an asset's current valuation is fair relative to its growth trajectory. By analyzing the undervaluation-to-growth indicator on the GURU.Markets platform, an investor can identify the potential of Regulus Therapeutics (RGLS) by assessing how closely the market price aligns with the company's ambitions to develop breakthrough microRNA therapies for the treatment of polycystic kidney disease.
Competing companies
PEG Multiple Tempus AI, Inc (TEM)|Price/Earnings to Growth Ratio Qiagen Group QGEN|Isis Pharmaceuticals - Price/Earnings to Growth Ratio|RGEN: Price/Earnings to Growth Multiple|RNA - PEG Multiple|CRISPR Therapeutics (CRSP) - Price/Earnings to Growth Ratio|WGS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple RARE|BEAM: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|Company Value to Earnings Growth Ratio TWST|PEG Multiple TXG (10x Genomics)|Growth-Adjusted Payback Ratio NTLA|Stoke - PEG Multiple|Price to Earnings Adjusted for Growth Rate BioLife|Wave Life Sciences (WVE) - Price/Earnings to Growth Ratio|mazetx.com - Growth-Adjusted Payback Ratio|SION (Sionna Therapeutics) - PEG Multiple|PEG Multiple Prime Medicine Inc|Price/Earnings to Growth Ratio Taysha (TSHA)|QURE: Market Cap to Earnings and Growth Ratio|PEG Multiple MGTX (MeiraGTx Holdings plc)|regenxbio.com (RGNX) - Price to Earnings Adjusted for Growth Rate|SLDB: Price/Earnings to Growth Multiple|OCGN - PEG Multiple|PACB (Pacific Biosciences of California) - Price/Earnings to Growth Multiple|BNTC: Company Value to Earnings Growth Ratio|DSGN (Design Therapeutics) - PEG Multiple|rocketpharma.com (RCKT) - Growth-Adjusted Market Cap to Net Income|PEG Multiple FDMT|Price/Earnings to Growth Multiple lexeotx.com LXEO|Price/Earnings to Growth Ratio Korro Bio KRRO|Growth-Adjusted Market Cap to Net Income Editas Corp (EDIT)|SLN - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio PRQR (ProQR Therapeutics N.V.)|CDXS: PEG Multiple|Price to Net Income Growth Ratio Sangamo Therapeutics Inc. SGMO|Price/Earnings to Growth Ratio Nautilus Biotechnology, Inc.|Price/Earnings to Growth Ratio MGX|Price/Earnings to Growth Ratio Precision BioSciences (DTIL)|Growth-Adjusted Market Cap to Net Income generationbio.com|PEG Multiple BOLD (Boundless Bio)|XCUR: Growth-Adjusted P/E Ratio|IMNN - Price/Earnings to Growth Ratio|PHIO (Phio Pharmaceuticals) - Growth-Adjusted P/E Ratio|MBIO: PEG Multiple|TransCode Therapeutics, Inc. (RNAZ) - PEG Multiple|Price/Earnings to Growth Ratio Bionano Genomics Inc.|APDN: Growth-Adjusted Payback Ratio|PEG Multiple BLUE|IPA - Price to Earnings Adjusted for Growth Rate|PEG Multiple OMGA (Omega Therapeutics)|Price to Net Income Growth Ratio singulargenomics.com|SYRS: Price/Earnings to Growth Multiple|TBIO - PEG Multiple|TRACON (TCON) - Price/Earnings to Growth Ratio|UBX (Unity Biotechnology, Inc) - Price/Earnings to Growth Ratio
